Ikarian Capital, LLC Clovis Oncology, Inc. Transaction History

Ikarian Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.05 - $2.85 $63,862 - $173,339	-60,821 Reduced 14.4%	361,518 $430,000
Q2 2022 Aug 12, 2022	SELL	$0.63 - $2.96 $220,500 - $1.04 Million	-350,000 Reduced 45.32%	422,339 $761,000
Q1 2022 May 13, 2022	SELL	$1.43 - $3.14 $486,671 - $1.07 Million	-340,330 Reduced 30.59%	772,339 $1.56 Million
Q3 2021 Nov 15, 2021	SELL	$4.06 - $5.8 $68,224 - $97,463	-16,804 Reduced 1.49%	1,112,669 $4.96 Million
Q2 2021 Aug 16, 2021	BUY	$5.02 - $7.05 $2.26 Million - $3.17 Million	450,000 Added 66.23%	1,129,473 $6.55 Million
Q1 2021 May 17, 2021	BUY	$4.81 - $10.34 $179,725 - $386,354	37,365 Added 5.82%	679,473 $4.77 Million
Q4 2020 Feb 12, 2021	SELL	$4.13 - $6.41 $471,348 - $731,560	-114,128 Reduced 15.09%	642,108 $3.08 Million
Q3 2020 Nov 16, 2020	BUY	$4.82 - $7.72 $3.57 Million - $5.72 Million	741,318 Added 4969.29%	756,236 $4.41 Million
Q2 2020 Aug 14, 2020	SELL	$5.69 - $9.69 $2.26 Million - $3.85 Million	-397,000 Reduced 96.38%	14,918 $101,000
Q1 2020 May 15, 2020	BUY	$3.77 - $11.0 $1.55 Million - $4.53 Million	411,918 New	411,918 $2.62 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.